Journal of Medicinal Chemistry · 2004 · 89 citations · 15 references
PharmacyMedicinal ChemistryPharmacologyAntimicrobial PharmacologyDrug DesignDrug DiscoveryAntibacterial AgentsAntibacterial PharmacologyAntibacterial TherapyEnzyme InhibitionPulmonary TuberculosisTuberculosis PharmacotherapyIn Vivo Efficacy TestingIn Vivo StudiesMycobacterium Tuberculosis InfectionTuberculosis Drug DevelopmentTuberculosis Drug Resistance
In an effort to develop new and more potent therapies to treat tuberculosis, a library of compounds was screened for M. tuberculosis UDP-Gal mutase inhibition. Nitrofuranylamide 1 was identified as a hit in this screen, possessing good antituberculosis activity. This paper describes the synthesis and evaluation of an expanded set of nitrofuranylamides. We have discovered a number of nitrofuranylamides with submicromolar M. tuberculosis MIC values and acceptable therapeutic indexes. The MIC activity did not correlate with UDP-Gal mutase inhibition, suggesting an alternative primary cellular target was responsible for the antituberculosis activity. The compounds were only active against mycobacteria of the tuberculosis complex. On the basis of these results, four compounds were selected for in vivo testing in a mouse model of tuberculosis infection, and of these compounds one showed significant antituberculosis activity.
15
Axonal Swellings and Degeneration in Mice Lacking the Major Proteolipid of Myelin
Ian R. Griffiths, Matthias Klugmann, Thomas Anderson et al. · Science · 1998 · 890 citations
Medicine, Neurobiology, Neuroscience +17
Inhibition of a <i>Mycobacterium tuberculosis</i> β-Ketoacyl ACP Synthase by Isoniazid
Khisimuzi Mdluli, Richard A. Slayden, Ya-Qi Zhu et al. · Science · 1998 · 397 citations